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Objective: To analyze the serum levels of miR-126, miR-146a and its relationship with
infarction area, severity of disease and inﬂammatory reaction degree in patients with
acute cerebral infarction (ACI).
Methods: A total of 75 cases with ACI treated in our hospital from April 2014 to
October 2015 and 80 healthy cases were respectively selected as ACI group and control
group for retrospective study. Patients' clinical data were collected, and the serum levels
of miR-126, miR-146a, tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and IL-6
were detected.
Results: Serum contents of miR-126 (0.286 ± 0.078 vs. 1.000 ± 0.169) and miR-146a
(0.337 ± 0.084 vs. 1.000 ± 0.158) in patients of ACI group were signiﬁcantly lower
than those of control group. Contents of IL-1b [(68.4 ± 10.3) vs. (22.7 ± 5.8) ng/L], TNF-
a [(126.9 ± 22.4) vs. (49.6 ± 8.4) ng/L] and IL-6 [(89.3 ± 14.7) vs. (34.8 ± 5.9) ng/L]
were obviously higher than those of control group. The bigger the infarction area was, the
more severer the degree of nerve defect could be. The lower the serum levels of miR-126,
miR-146a were, the higher the levels of TNF-a, IL-1b, IL-6 could be. Levels of miR-126
and miR-146a were negative correlation with levels of TNF-a, IL-1b and IL-6.
Conclusions: An abnormal decrease in serum levels of miR-126 and miR-146a in pa-
tients with ACI was closely related to the severity of disease. Through regulating the
generation of inﬂammatory factors TNF-a, IL-1b and IL-6, miR-126 and miR-146a may
get involved in the changes of cerebral infarction condition.1. Introduction
Acute cerebral infarction (ACI) is a cerebrovascular disease
which causes serious harm to human health, and its disability rate
and fatality rate are relatively high[1–3]. Atherosclerosis is an
important pathological basis for causing the occurrence and
development of ACI. The formation and character change of
atheromatous plaque are the core links of causing thedevelopment and change of cerebral infarction condition[4–6]. At
present, great progress has been made clinically in the diagnosis
and treatment of cerebral infarction. With the development of
thrombolytic therapy, interventional therapy, functional exercise
during convalescence, neurotrophy, and other measures,
prognosis in patients with cerebral infarction has been improved
greatly. In spite of this, the pathogenesis of cerebral infarction,
especially the pathogenesis of atherosclerosis is not clear yet.
miRNA is a non-coding RNA with the length of 17–25 bp, and
its function is to target and induce degradation or translation in-
hibition of mRNA, thereby causing gene silence at a post-
transcriptional level. miRNA involves in various in-vivo post-
transcriptional control of genetic expression, which has regu-
lating effect on the mature of neurological function, formation of
atheromatous plaque, immune and inﬂammatory response[7–9]. In
the process of the occurrence and development of cerebral
infarction and atherosclerosis, various miRNAs play an
important role in regulation. Studies have shown that twoarticle under the CC BY-NC-ND license (http://
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atherosclerosis by targeting and regulating inﬂammatory response,
and their abnormal content relate to various cardiovascular and
cerebrovascular diseases[10,11]. In the following study, we analyzed
the serum levels of miR-126, miR-146a and their relationship
with severity of disease in patients with ACI.
2. Materials and methods
2.1. Study objects
Using the method of retrospective study, 75 cases of patients
with ACI treated in our hospital from April 2014 to October
2015 were selected as the ACI group. All patients met the
diagnostic criteria of cerebral infarction deﬁned by the Fourth
National Academic Conference on Cerebral Vascular Disease.
These patients were sent to the hospital after onset in 48 h, and
did not receive thrombolytic and volume expansion therapies
before collecting blood samples. Patients with merge malignant
tumor, serious infection and autoimmune disease were excluded.
Eighty healthy cases that match the data of ACI group patients
were selected as control group. This study was approved by the
Hospital Ethics Committees, and obtained the informed consent
from subjects tested.
Head MRI and diffusion-weighted imaging were carried out
in patients of ACI group after admission, and the maximum
diameter of infarct < 1.5 cm was considered as lacunar infarc-
tion; the maximum diameter of infarct 1.5–3.0 cm was consid-
ered as small infarct, and  3.0 cm was considered as large
infarct. The National Institutes of Health Stroke Scale (NIHSS)
was performed before treatment, NIHSS < 7 was slight type; 7–
15 was moderate type, and > 15 was serious type.
2.2. Study methods
Reviewing the case data in patients of ACI group and the
medical examination report in healthy group, gender, age,
height, weight and blood pressure were collected. Peripheral
blood in patients of ACI group was collected after admission.
Peripheral blood of control group was collected during physical
examination. Serum was took after the sodium citrate anti-
coagulation and kept at −80 C. Proper amount of blood sample
was used to extract total miRNA by using miRcute miRNA
isolation kit (DP501). miRNA was reverse-transcribed into
corresponding cDNA by using miRcute miRNA cDNA ﬁrst-
stand cDNA (KR201). Finally, contents of miR-126 and miR-
146a were detected by using ﬂuorescence PCR and ancillary
SYBR Green (FP401). Besides, proper amount of blood sample
was used to detect the content of tumor necrosis factor-a (TNF-
a), interleukin-1b (IL-1b) and IL-6 by using ELIASA and
ancillary ELIASA kit.Table 1
Clinical data in two groups objects.
Group Gender (male/female) Age (year
ACI group (n = 75) 45/30 54.2 ± 7.2
Control group (n = 80) 50/30 52.8 ± 8.4
P > 0.05 > 0.052.3. Statistical analysis
Using SPSS version 19.0 for entering and analyzing data,
measurement data were expressed by mean ± SD, and data be-
tween two groups were analyzed by t-test, and data among three
groups were analyzed by ANOVA. Enumeration data were
expressed by frequency and analyzed by Chi-square test. Corre-
lations between two variables were tested by Pearson's correla-
tion analysis. P < 0.05 was considered as statistical signiﬁcance.
3. Results
3.1. Clinical data of two groups
Among 75 cases of ACI group, male was 45 and female was
30, with mean age of (54.2 ± 7.2) years, bogy mass index (BMI)
(22.1 ± 3.9) kg/m2, systolic blood pressure (SBP) (135.9 ± 16.9)
mmHg, diastolic blood pressure (DBP) (84.5 ± 10.1) mmHg.
Among 80 healthy cases of control group, male was 50 and
female was 30, with mean age of (52.8 ± 8.4) years, BMI
(22.8 ± 4.4), SBP (132.4 ± 15.4) mmHg, DBP (83.9 ± 11.4)
mmHg. According to statistic analysis, there was no signiﬁcant
difference among gender, age, BMI, SBP, and DBP in patients
with ACI (Table 1).
3.2. Comparison of serum index between two groups'
objects
Contents of serummiR-126 (0.286 ± 0.078 vs. 1.000 ± 0.169),
miR-146a (0.337 ± 0.084 vs. 1.000 ± 0.158) in patients of ACI
group were signiﬁcantly lower than those of control group, and
contents of miR-126 (0.286 ± 0.078 vs. 1.000 ± 0.169), miR-146a
(0.337 ± 0.084 vs. 1.000 ± 0.158) were obviously lower higher
than those of control group. Contents of low density lipoprotein
cholesterol, high density lipoprotein cholesterol, blood urea ni-
trogen and serum creatinine have no signiﬁcant difference with
control group (Table 2).
3.3. Serum index in patients of ACI group with different
infarction area
The serum levels of miR-126 (0.682 ± 0.114 vs. 0.392 ± 0.063
vs. 0.167 ± 0.032), miR-146a (0.705 ± 0.121 vs. 0.417 ± 0.088 vs.
0.198 ± 0.027) and IL-1b [(36.9 ± 6.5) vs. (64.9 ± 8.9) vs.
(95.1 ± 13.7) ng/L], TNF-a [(70.5 ± 11.4) vs. (104.2 ± 13.2) vs.
(160.3 ± 26.9) ng/L], IL-6 [(65.8 ± 10.3) vs. (84.8 ± 12.6) vs.
(171.3 ± 24.8) ng/L] in patients of ACI group with different
infarction area have signiﬁcant difference. The bigger infrac-
tion area was, the lower serum levels in miR-126 and miR-
146a could be, and levels in IL-1b, TNF-a and IL-6 were
higher (Table 3).) BMI (kg/m2) SBP (mmHg) DBP (mmHg)
22.1 ± 3.9 135.9 ± 16.9 84.5 ± 10.1
22.8 ± 4.4 132.4 ± 15.4 83.9 ± 11.4
> 0.05 > 0.05 > 0.05
Table 2
Comparison of serum index between two groups' objects.
Group miR-126/U6 miR-146a/U6 IL-1b
(ng/L)
TNF-a
(ng/L)
IL-6
(ng/L)
LDL-C
(mmol/L)
HDL-C
(mmol/L)
BUN
(mmol/L)
Scr
(mmol/L)
ACI group (n = 75) 0.286 ± 0.078 0.337 ± 0.084 68.4 ± 10.3 126.9 ± 22.4 89.3 ± 14.7 3.9 ± 0.6 1.7 ± 0.2 5.6 ± 0.55 68.1 ± 10.2
Control group
(n = 80)
1.000 ± 0.169 1.000 ± 0.158 22.7 ± 5.8 49.6 ± 8.4 34.8 ± 5.9 4.1 ± 0.5 1.6 ± 0.2 5.9 ± 0.9 66.3 ± 9.7
P < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 > 0.05 > 0.05 > 0.05 > 0.05
LDL-C: Low density lipoprotein cholesterin; HDL-C: High density lipoprotein cholesterol; Scr: Serum creatinine; BUN: Blood urea nitrogen.
Table 3
Serum index in patients of ACI group with different infarction area.
Different infarction area miR-126/U6 miR-146a/U6 IL-1b (ng/L) TNF-a (ng/L) IL-6 (ng/L)
Lacunar infarct 0.682 ± 0.114 0.705 ± 0.121 36.9 ± 6.5 70.5 ± 11.4 65.8 ± 10.3
Small area infarcts 0.392 ± 0.063 0.417 ± 0.088 64.9 ± 8.9 104.2 ± 13.2 84.8 ± 12.6
Large area of infarcts 0.167 ± 0.032 0.198 ± 0.027 95.1 ± 13.7 160.3 ± 26.9 171.3 ± 24.8
P < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Table 4
Serum index in patients of ACI group with different severity.
Different severity miR-126/U6 miR-146a/U6 IL-1b (ng/L) TNF-a (ng/L) IL-6 (ng/L)
Slight cerebral infarction 0.669 ± 0.104 0.712 ± 0.118 41.3 ± 7.1 73.1 ± 10.8 62.2 ± 9.8
Moderate cerebral infarction 0.415 ± 0.069 0.427 ± 0.091 62.2 ± 8.2 112.8 ± 12.8 82.1 ± 11.9
Serious cerebral infarction 0.154 ± 0.029 0.176 ± 0.024 92.5 ± 12.9 159.1 ± 22.5 168.5 ± 22.7
P < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
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severity
Serum miR-126, miR-146a and levels of IL-1b, TNF-a, IL-6
in patients of ACI group with different severity have obviously
difference. The bigger infarction area was, the lower levels in
serum miR-126 (0.669 ± 0.104 vs. 0.415 ± 0.069 vs. 0.154 ±
0.029) and miR-146a could be (0.712 ± 0.118 vs. 0.427 ± 0.091
vs. 0.176 ± 0.024), and levels in IL-1b [(41.3 ± 7.1) vs. (62.2 ±
8.2) vs. (92.5 ± 12.9) ng/L], TNF-a [(73.1 ± 10.8) vs. (112.8 ±
12.8) vs. (159.1 ± 22.5) ng/L] and IL-6 were higher [(62.2 ± 9.8)
vs. (82.1 ± 11.9) vs. (168.5 ± 22.7) ng/L] (Table 4).
4. Discussion
Atherosclerosis is an important pathological basis causing
ACI. The change of plaque and the rupture of ﬁbrous cap will
activate coagulation process, causing thrombogenesis, so as to
result in nerve function deﬁcit by various pathophysiology[12–15].
At present, the character change in arterial plaque and the
follow-up molecular mechanism of nerve function deﬁcit have
not been completely clariﬁed. miRNA is an endogenous non-
coding single-stranded RNA with the length of 21–25 bp,
involving with in-vivo regulation in various genetic expression
and multiple biological processes. Previous studies indicated
that the change of miRNAs content is related to atherosclerosis,
plaque characteristic change and rupture, nerve function deﬁcit,
inﬂammation and imbalance of immunoreactions, in which
abnormal contents of two miRNAs, miR-126 and miR-146a are
related to various cardiovascular and cerebrovascular diseases[16–
20]. We analyzed the above two miRNAs contents in serum, and
the analysis indicated that an abnormal decrease in serum miR-126 and miR-146a of patients with ACI is related to infraction
area and neurologic impairment degree.
Inﬂammatory response is an important pathological change
throughout various pathological processes of ACI. And links such
as atherosclerosis, formation of plaque, character changes,
formation of thrombus and neuron damage are involved in the
activation of inﬂammatory reaction, aggregation of inﬂammatory
cell and the synthesis and release of inﬂammatory factors[21–23].
IL-1b is an immunomodulatory factor with extensive biological
activity, which can regulate the synthesis, secretion and release
of various inﬂammatory mediators, making synergistic effect
in inﬂammatory response[24]. TNF-a is an initial factor of inﬂa-
mmatory response in the process of cerebral infarction and
ischemia reperfusion, which can directly cause brain tissue
damage, induce cascade ampliﬁcation of inﬂammatory response
in local tissue and aggravate inﬂammatory response[22]. IL-6 has
various biological functions, which can recruit inﬂammatory cell
in local tissue, activate expression of inﬂammatory factor, as well
as simultaneously cause edema of brain tissue and aggravate
neurologic deﬁcit[25]. We analyzed the content of inﬂammatory
factor in serum, and results have shown that contents of TNF-a,
IL-1b and IL-6 in patients with ACI elevating abnormally were
related to infraction area and neurologic impairment degree.
NF-kB is an important transcription factor regulating in-
ﬂammatory response in vivo, which can initiate expression of
various inﬂammatory factors after activating[26,27]. In addition,
when inﬂammatory response of body was activated,
interleukin-1 receptor-associated kinase 1 and tumor necrosis
factor receptor associated factor-6 were activated and were able
to promote the generation of various inﬂammatory factors[28,29].
Previous studies have indicated that miR-126 and miR-146a
can targeting regulate NF-kB, IRAK-l and TRAF-6 and
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further prove if miR-126 and miR-146a involve in the occur-
rence of cerebral infarction and the development of disease
through targeting and regulating the generation of inﬂammatory
factors TNF-a, IL-1b and IL-6. Pearson's correlation analysis
was used to verify the relationship of serum levels of miR-126
and miR-146a with TNF-a, IL-1b and IL-6. Results showed
that levels of miR-126 and miR-146a were negatively correlated
with levels of TNF-a, IL-1b and IL-6, which suggested that
miR-126 and miR-146a might involve in regulating the ex-
pressions of TNF-a, IL-1b and IL-6, and it can not only directly
target toward the above 30UTR of inﬂammatory factor mRNA to
inhibit the expression of gene, but also indirectly regulate the
generation of the above inﬂammatory factor by targeting TRAF-
6, IRAK-1 and NF-kB. Speciﬁc molecular pathways that miR-
126 and miR-146a regulate the generation of TNF-a, IL-1b
and IL-6, were also needed to verify by in-vitro study.
In conclusion, an abnormal decrease in serum levels of miR-
126 and miR-146a in patients with ACI is closely related to the
severity of disease. miR-126 and miR-146a might involve in the
change of severity of cerebral infarction through regulating in-
ﬂammatory factors TNF-a, IL-1b and IL-6.
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